Mirum Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MIRUM, and what generic alternatives to MIRUM drugs are available?
MIRUM has two approved drugs.
There are seven US patents protecting MIRUM drugs.
There are one hundred and eleven patent family members on MIRUM drugs in twenty-two countries and sixteen supplementary protection certificates in eleven countries.
Drugs and US Patents for Mirum
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mirum | LIVMARLI | maralixibat chloride | SOLUTION;ORAL | 214662-001 | Sep 29, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Mirum | LIVMARLI | maralixibat chloride | SOLUTION;ORAL | 214662-001 | Sep 29, 2021 | RX | Yes | Yes | 11,229,647 | ⤷ Sign Up | ⤷ Sign Up | ||||
Mirum | LIVMARLI | maralixibat chloride | SOLUTION;ORAL | 214662-002 | Jul 24, 2024 | RX | Yes | Yes | 11,229,661 | ⤷ Sign Up | ⤷ Sign Up | ||||
Mirum | LIVMARLI | maralixibat chloride | SOLUTION;ORAL | 214662-001 | Sep 29, 2021 | RX | Yes | Yes | 11,260,053 | ⤷ Sign Up | ⤷ Sign Up | ||||
Mirum | CHOLBAM | cholic acid | CAPSULE;ORAL | 205750-002 | Mar 17, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Mirum | LIVMARLI | maralixibat chloride | SOLUTION;ORAL | 214662-001 | Sep 29, 2021 | RX | Yes | Yes | 11,376,251 | ⤷ Sign Up | ⤷ Sign Up | ||||
Mirum | LIVMARLI | maralixibat chloride | SOLUTION;ORAL | 214662-001 | Sep 29, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Mirum Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
European Patent Office | 3593802 | ⤷ Sign Up |
Japan | 2014532662 | ⤷ Sign Up |
Singapore | 10201406155Q | ⤷ Sign Up |
Mexico | 2019013263 | ⤷ Sign Up |
Japan | 6217938 | ⤷ Sign Up |
Eurasian Patent Organization | 038594 | ⤷ Sign Up |
European Patent Office | 2771003 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Mirum Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2771003 | 301234 | Netherlands | ⤷ Sign Up | PRODUCT NAME: MARALIXIBAT OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER MARALIXIBATCHLORIDE; REGISTRATION NO/DATE: EU/1/22/1704 20221212 |
2771003 | C202330025 | Spain | ⤷ Sign Up | PRODUCT NAME: MARALIXIBAT O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN PARTICULAR CLORURO DE MARALIXBAT; NATIONAL AUTHORISATION NUMBER: EU/1/22/1704; DATE OF AUTHORISATION: 20221209; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/22/1704; DATE OF FIRST AUTHORISATION IN EEA: 20221209 |
2771003 | 2023C/521 | Belgium | ⤷ Sign Up | PRODUCT NAME: MARALIXIBAT, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE CHLORURE DE MARALIXIBAT; AUTHORISATION NUMBER AND DATE: EU/1/22/1704 20221212 |
2380576 | 2020/043 | Ireland | ⤷ Sign Up | PRODUCT NAME: DEOXYCHOLIC ACID SODIUM SALT; NAT REGISTRATION NO/DATE: PA2103/003/001 20170602; FIRST REGISTRATION NO/DATE: SE/H/1547/001/DC 20160729 |
1392714 | CR 2017 00025 | Denmark | ⤷ Sign Up | PRODUCT NAME: OBETICHOLIC ACID; REG. NO/DATE: EU/1/16/1139 20161215 |
2380576 | SPC/GB20/050 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: DEOXYCHOLIC ACID SODIUM SALT; REGISTERED: UK PL 45496/0009 20170526 |
2771003 | 23C1022 | France | ⤷ Sign Up | PRODUCT NAME: MARALIXIBAT, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE MARALIXIBAT, EN PARTICULIER LE CHLORURE DE MARALIXIBAT; REGISTRATION NO/DATE: EU/1/22/1704 20221212 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.